Cargando…

Absence of copy number gain of EGFR: A possible predictive marker of long‐term response to afatinib

Treatment efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) is diverse even in non‐small cell lung cancer (NSCLC) patients with EGFR activating mutations. Extraordinary long‐term responses sustained over 3 years among NSCLC patients treated with afatinib, an EGFR‐TKI,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Tomomi, Sato, Akemi, Nakashima, Chiho, Abe, Tomonori, Iwanaga, Kentaro, Umeguchi, Hitomi, Kawaguchi, Atsushi, Sueoka‐Aragane, Naoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986088/ https://www.ncbi.nlm.nih.gov/pubmed/36382532 http://dx.doi.org/10.1111/cas.15655

Ejemplares similares

SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer
por: Komiya, Kazutoshi, et al.
Publicado: (2016)

Automated DNA extraction using cellulose magnetic beads can improve EGFR point mutation detection with liquid biopsy by efficiently recovering short and long DNA fragments
por: Nakashima, Chiho, et al.
Publicado: (2018)

Origin of circulating free DNA in patients with lung cancer
por: Abe, Tomonori, et al.
Publicado: (2020)

Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
por: Harada, Yohei, et al.
Publicado: (2023)

Investigation of appropriate pre-analytical procedure for circulating free DNA from liquid biopsy
por: Sato, Akemi, et al.
Publicado: (2018)

Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
por: Nakamura, Tomomi, et al.
Publicado: (2018)

Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer
por: Komiya, Kazutoshi, et al.
Publicado: (2019)

Acute Generalized Exanthematous Pustulosis Caused by Erlotinib in a Patient with Lung Cancer
por: Komiya, Natsuko, et al.
Publicado: (2021)

Successful Surgical Resection following Bronchial Artery Embolization in a Case of Lung Cancer Complicated with Massive Hemoptysis
por: Sadamatsu, Hironori, et al.
Publicado: (2018)

ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies
por: Matsumoto, Akiko, et al.
Publicado: (2021)

Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study
por: Sueoka‐Aragane, Naoko, et al.
Publicado: (2016)

The role of comprehensive analysis with circulating tumor DNA in advanced non‐small cell lung cancer patients considered for osimertinib treatment
por: Sueoka‐Aragane, Naoko, et al.
Publicado: (2021)

Paraneoplastic Limbic Encephalitis Complicated with Small Cell Lung Cancer at the Time of Recurrence
por: Sadamatsu, Hironori, et al.
Publicado: (2019)

Integrated approach to functional analysis of an ERBB2 variant of unknown significance detected by a cancer gene panel test
por: Harada, Yohei, et al.
Publicado: (2022)

Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report
por: Hirakawa, Haruki, et al.
Publicado: (2017)

A Low Body Mass Index Is Associated with Unsuccessful Treatment in Patients with Mycobacterium avium Complex Pulmonary Disease
por: Sadamatsu, Hironori, et al.
Publicado: (2021)

Factors related to the diagnosis of lung cancer by transbronchial biopsy with endobronchial ultrasonography and a guide sheath
por: Kurihara, Yuki, et al.
Publicado: (2022)

Response of Leptomeningeal Metastases in EGFR-Mutated Non-Small-Cell Lung Cancer to Afatinib in the Absence of Radiotherapy
por: Llinás-Quintero, Néstor, et al.
Publicado: (2019)

EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
por: Sesboüé, R, et al.
Publicado: (2012)

Correlation between Plasma DNA and Tumor Status in an Animal Model
por: Sueoka-Aragane, Naoko, et al.
Publicado: (2014)

Coexistence of lung cancer and immunoglobulin G4-related lung disease in a nodule: a case report
por: Tashiro, Hiroki, et al.
Publicado: (2016)

Successful treatment of pulmonary nocardiosis with fluoroquinolone in bronchial asthma and bronchiectasis
por: Sadamatsu, Hironori, et al.
Publicado: (2017)

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
por: Oya, Yuko, et al.
Publicado: (2021)

Reply: EGFR alterations and response to anti-EGFR therapy: is it a matter of gene amplification or gene copy number gain?
por: Ålgars, A, et al.
Publicado: (2012)

Severe eosinophilic pneumonia presenting during gemcitabine adjuvant chemotherapy
por: Yakabe, Tomomi, et al.
Publicado: (2013)

Sjögren Syndrome Complicated with Cystic Lung Disease and Pulmonary Amyloidosis
por: Takahashi, Koichiro, et al.
Publicado: (2018)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC
por: Wei, Jiacong, et al.
Publicado: (2021)

Transformation to small cell lung cancer after first-line afatinib treatment
por: Shiroyama, Takayuki, et al.
Publicado: (2018)

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2019)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

Development of Lymphoproliferative Diseases by Hypoxia Inducible Factor-1alpha Is Associated with Prolonged Lymphocyte Survival
por: Sueoka, Eisaburo, et al.
Publicado: (2013)

Analysis of rare copy number variation in absence epilepsies
por: Addis, Laura, et al.
Publicado: (2016)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
por: Harvey, R Donald, et al.
Publicado: (2020)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
por: Wei, Yang, et al.
Publicado: (2021)

Glioblastomas with copy number gains in EGFR and RNF139 show increased expressions of carbonic anhydrase genes transformed by ENO1
por: Beckner, Marie E., et al.
Publicado: (2015)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Copy number variants in absence epilepsy: Further complications of the picture
por: Depondt, Chantal
Publicado: (2016)

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
por: Nakao, Keiko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gvq2gdhbtsgsgbm7iip9g7dbq8